Results from our study indicated that immPRF treatment after nerve injury mediated inhibition of SNI-induced IGF2, and ERK1/2 activation via spinal microglia may be a possible mechanism underlying its inhibitory action on SNI-induced neuropathic pain. This evidence concerns the gene MAPK3 and Pain.